Research thatreshaped strategy.
Selected engagements from our Private Equity and Healthcare & Life Sciences practices.
As customers adopt AI across research and development workflows, does demand for physical consumables and analytical instruments grow, hold, or quietly erode?
How much unmet need do patients still carry in a market clinicians describe as well-served, and which treatment attributes actually move their choice of therapy?
Where is a global CRO's brand earned, where is it exposed, and does the answer change across buyer segments and functions?
Could a fragmented laboratory consumables category be sized at the instrument-category level, precisely enough to underwrite a market-entry decision?
Two candidate brand identities, four markets, two audiences: which version carries the company's mission, and does the same content even read the same way in every market?
Would a savings-realization story and three solution concepts carry an upcoming campaign, tested blind with the exact committee it targets?
Does a mature two-marker inflammation testing category hold enough unmet need to justify platform entry?
Is the flagship brand's equity holding independently, or is it being absorbed by the corporate master brand it sits under?
How durable is the incumbents' hold on oncology real-world evidence, and do buyers reward the data assets a new entrant from the pharmaceutical services value chain could uniquely supply?
Where does the diagnostic journey lose time, which patients lose it, and what do they wish had been explained?
Clinical urgency starts the conversation, finance controls every gate, coalition alignment closes the deal.
Three behavioral segments, one clear target, and a firmographic model the data overturned.